Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of pimicotinib (ABSK021) in chronic graft-versus-host disease
CTR20230954Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimicotinib in chronic graft-versus-host disease (cGVHD), sponsored by Abbisko Therapeutics. Started Jun 2023; status: active.
02
Drugs
pimicotinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20230954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230954.